LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Improved food safety through asparaginase produced via genetically modified micro-organisms: reduced acrylamide in cooked food

25/06/2021

Nominated by: DSM

Organisation in nomination: DSM and Novozymes    

Acrylamide can arise during the cooking process of foods via reaction of the amino acid asparagine and glucose, and is linked to negative health effects in humans, including cancer.  It is particularly formed during the high temperature cooking of plant-based foods with high carbohydrate levels, such as fried and baked potatoes, bread and bakery products and coffee.

Although acrylamide was identified as a potential food safety issue as far back as 2002, it was a European Food Safety Authority (EFSA) opinion on acrylamide in food in 2015 which led the European Commission (EC) to establish its risk management measures.

Whilst adaptation of cooking conditions may help reduce acrylamide formation, the use of asparaginase enzymes was determined as the best way to reduce acrylamide formation in the daily practice of food production.

Production of asparaginase enzymes from genetically engineered microorganisms started a mere 4 years after the potential risk was identified. This was a breakthrough solution, with the enzyme able to help reduce the formation of acrylamide during cooking and contributing to the safety of food in Europe.

Enzyme producers DSM and Novozymes developed Aspergillus strains as microorganisms for the over-expression of the enzyme asparaginase, enabling scale of production to meet the needs of the food industry. This would not have been technically and economically viable with classical strains of microorganisms.

References:

  • Palermo M, Gökmen V, De Meulenaer B, Ciesarová Z, Zhang Y, Pedreschi F, Fogliano V. Acrylamide mitigation strategies: critical appraisal of the FoodDrinkEurope

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.